JP2019511527A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511527A5
JP2019511527A5 JP2018553364A JP2018553364A JP2019511527A5 JP 2019511527 A5 JP2019511527 A5 JP 2019511527A5 JP 2018553364 A JP2018553364 A JP 2018553364A JP 2018553364 A JP2018553364 A JP 2018553364A JP 2019511527 A5 JP2019511527 A5 JP 2019511527A5
Authority
JP
Japan
Prior art keywords
disease
disorder
alkyl
muscle
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018553364A
Other languages
English (en)
Japanese (ja)
Other versions
JP6925367B2 (ja
JP2019511527A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/027327 external-priority patent/WO2017180818A1/en
Publication of JP2019511527A publication Critical patent/JP2019511527A/ja
Publication of JP2019511527A5 publication Critical patent/JP2019511527A5/ja
Application granted granted Critical
Publication of JP6925367B2 publication Critical patent/JP6925367B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018553364A 2016-04-13 2017-04-13 Pparアゴニスト、化合物、医薬組成物、及びその使用方法 Active JP6925367B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322017P 2016-04-13 2016-04-13
US62/322,017 2016-04-13
PCT/US2017/027327 WO2017180818A1 (en) 2016-04-13 2017-04-13 Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019511527A JP2019511527A (ja) 2019-04-25
JP2019511527A5 true JP2019511527A5 (enExample) 2020-06-18
JP6925367B2 JP6925367B2 (ja) 2021-08-25

Family

ID=58606595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553364A Active JP6925367B2 (ja) 2016-04-13 2017-04-13 Pparアゴニスト、化合物、医薬組成物、及びその使用方法

Country Status (10)

Country Link
US (1) US11358954B2 (enExample)
EP (1) EP3442948B1 (enExample)
JP (1) JP6925367B2 (enExample)
KR (1) KR102430906B1 (enExample)
CN (1) CN109071459B (enExample)
BR (1) BR112018069930B1 (enExample)
ES (1) ES2861503T3 (enExample)
MX (1) MX380531B (enExample)
RU (1) RU2746602C2 (enExample)
WO (1) WO2017180818A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016333963C1 (en) 2015-10-07 2021-05-27 The Salk Institute For Biological Studies PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
US11358954B2 (en) 2016-04-13 2022-06-14 Mitobridge, Inc. PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
CN109843857B (zh) * 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
CN113912547B (zh) 2020-07-10 2024-04-30 成都凡诺西生物医药科技有限公司 取代苯丙咪唑类衍生物及其应用
CN112479921B (zh) * 2020-12-04 2022-12-06 中国药科大学 具有PPARδ激动活性的化合物、药物组合物及医药用途
EP4015623A1 (en) 2020-12-17 2022-06-22 Universite De Montpellier Pre-treatment of msc with ppar beta/delta agonist for treatment of ischemia-reperfusion injury
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228281A (en) 1977-09-23 1980-10-14 Ciba-Geigy Corporation Dicarboxylic acids containing triazine rings
DE4123341A1 (de) 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
PT1311488E (pt) 2000-08-17 2009-12-30 Pfizer Ltd Imidazóis substituídos utilizados como inibidores de tafia
CA2495943C (en) 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles having anti-diabetic activity
EP1553075B1 (en) 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
WO2004060367A1 (en) 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
KR20070087197A (ko) 2003-09-26 2007-08-27 니뽄 다바코 산교 가부시키가이샤 잔여 리포프로테인 생산 저해 방법
JP2008512364A (ja) 2004-09-06 2008-04-24 エフ.ホフマン−ラ ロシュ アーゲー 4−アミノメチルベンズアミジン誘導体及び第VIIa因子阻害剤としてのその使用
KR20070097574A (ko) 2005-02-15 2007-10-04 에프. 호프만-라 로슈 아게 Ppar 활성화제로서의 아미드 유도체
CA2621406A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
EP1991544B1 (en) 2006-01-30 2018-08-15 vTv Therapeutics LLC Substituted imidazole derivatives and their use as ptpase inhibitors
CA2644369A1 (en) 2006-03-28 2007-10-04 Novartis Ag Amide derivatives and their application for the treatment of g protein related diseases
EP2014652B1 (en) 2006-04-18 2014-08-06 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
CN101085772A (zh) 2006-06-07 2007-12-12 上海艾力斯医药科技有限公司 一类具有PPARγ激动剂活性的化合物及其应用
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
US20100063041A1 (en) 2007-03-07 2010-03-11 Ho-Sang Moon Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
JP2008285452A (ja) 2007-05-21 2008-11-27 Ono Pharmaceut Co Ltd PPARα/γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬
CA2710764A1 (en) 2007-12-28 2009-07-09 The Salk Institute For Biological Studies Methods for enhancing muscle performance and tone
JP2016520552A (ja) 2013-04-05 2016-07-14 ソーク インスティテュート フォー バイオロジカル スタディーズ Pparアゴニスト
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
US20170305894A1 (en) 2014-10-08 2017-10-26 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
AU2016333963C1 (en) 2015-10-07 2021-05-27 The Salk Institute For Biological Studies PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
US11358954B2 (en) 2016-04-13 2022-06-14 Mitobridge, Inc. PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
UA124019C2 (uk) * 2016-10-05 2021-07-07 Мітобрідж, Інк. Спосіб лікування гострого пошкодження нирок

Similar Documents

Publication Publication Date Title
RU2018137521A (ru) Агонисты ppar, соединения, фармацевтические композиции и способы их применения
JP2020512298A5 (enExample)
JP2019529516A5 (enExample)
RU2019110736A (ru) Кристаллические и солевые формы соединений агонистов ppar
HRP20210887T1 (hr) Inhibitori poli-adp riboza polimeraze (parp)
US10968172B2 (en) USP30 inhibitors
JP2013516501A5 (enExample)
CN105307498B (zh) 用于治疗眼病的组合物、制剂和方法
NZ610230A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
JP5701308B2 (ja) 新規血管漏出遮断剤
EP3069612A2 (en) Dithiol compounds, derivatives, and uses therefor
JP2018508569A5 (enExample)
JP2018522042A5 (enExample)
JP2016516068A5 (enExample)
EP3209732B1 (en) Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
TW201943705A (zh) 過氧化物酶體增生劑活化之受體(ppar)促效劑其化合物其醫藥組合物及其使用方法
JP2017534665A5 (enExample)
CN111712489A (zh) 用于治疗神经肌肉病症的化合物
IL259381A (en) Mirabegron for the treatment of retinal diseases
CN114008012A (zh) 用于治疗神经肌肉病症的化合物
US10758511B2 (en) Stable analogs of CYP450 lipid metabolites and inhibitors of soluble epoxide hydrolase
TH1901003991A (th) สารยับยั้งของ พอลิ-adp ไรโบส พอลิเมอเรส (parp)
WO2016001682A1 (en) Treatment of hypertransaminasemia
CN105073109A (zh) 眼部疾病用治疗剂
TW202537626A (zh) 含磷bcl抑制劑及抗衰老化合物及其用途